Xenetic Biosciences, Inc. (XBIO)

Advancing Innovative Immune-Oncology Technologies

We are a biopharmaceutical company focused on advancing proprietary technology platforms across multiple high-value cancer indications.

More About Us

Targeting Neutrophil Extracellular Traps (NETs)

NETs are a driver of cancer progression and metastasis and can also contribute to resistance to chemotherapy, checkpoint inhibitors and radiotherapy.

DNase I Oncology Platform

Oncology platform aimed at improving cancer therapies with the opportunity to address multiple oncology indications, including pancreatic cancer and other solid tumors.

Pipeline

Latest News

Jul 08, 2025

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

May 14, 2025

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Stock Information • View Detailed Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.

Price

Change

Volume

Day Range

52 Week Range

Get Email Alerts

Stay informed about our latest news and updates